Abstracts tagged "rheumatoid arthritis"

Abstract Number: 1747 • ACR Convergence 2025
Risk of serious infection in patients with rheumatoid arthritis-associated interstitial lung disease or bronchiectasis: A matched cohort study
QIANRU ZHANG¹, Ying Qi², Xiaosong Wang³, Gregory McDermott⁴, Sung Hae Chang⁵, Mark Chaballa⁶, Vadim Khaychuk⁷, Misti Paudel⁸ and Jeffrey Sparks⁹, ¹Brigham and Women’s Hospital/Beijing Tsinghua Changgung Hospital, Cambridge, MA, ²Brigham and Women’s Hospital, Boston, ³Brigham and Women's Hospital, Natick, MA, ⁴Brigham and Women's Hospital, Brookline, MA, ⁵Soonchunhyang University College of Medicine, Cheonan, MA, South Korea, ⁶Bristol Myers Squibb, Princeton, NJ, ⁷Bristol Myers Squibb, Pennington, NJ, ⁸Brigham and Women's Hospital, Division of Rheumatology, Inflammation, and Immunity, Boston, MA, ⁹Brigham and Women's Hospital, Boston, MA
Background/Purpose: RA-associated lung disease (RA-LD), including RA-associated interstitial lung disease (RA-ILD) and RA-associated bronchiectasis (RA-BR), contributes significantly to morbidity and mortality in RA patients. RA…
Abstract Number: 1674 • ACR Convergence 2025
A Phase 2, Randomized, Placebo-Controlled Trial of Hydroxychloroquine in Individuals At-Risk for Future Rheumatoid Arthritis
Kevin Deane¹, Christopher Striebich², Marie Feser³, James O'Dell⁴, Judith James⁵, Jeffrey Sparks⁶, John Davis⁷, Jonathan Graf⁸, Maureen McMahon⁹, Elizabeth Solow¹⁰, Lindsy Forbess¹¹, Athan Tiliakos¹², Elena Schiopu¹³, David Fox¹⁴, Maria I. ("Maio") Danila¹⁵, Diane Horowitz¹⁶, Jonathan Kay¹⁷, Colin Strickland³, Joel Guthridge⁵, Cristina Arriens⁵, Jennifer Grossman¹⁸, Kristen Demoruelle¹⁹, Elizabeth Bemis³, Ashley Frazer-Abel³, Chelsie Fleischer²⁰, Ted Mikuls⁴, Melissa Greenleaf²¹, Kate York²², Sarah Walker²³, Lynette Keyes-Elstein²³, Margie Byron²³, Janel Fedler²⁴, Ellen Goldmuntz²⁵ and V. Michael Holers²⁶, ¹University of Colorado Denver Anschutz Medical Campus, Aurora, CO, ²University of Colorado, Aurora, CO, ³University of Colorado Anschutz Medical Campus, Aurora, CO, ⁴University of Nebraska Medical Center, Omaha, NE, ⁵Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁶Brigham and Women's Hospital, Boston, MA, ⁷Mayo Clinic, Rochester, MN, ⁸UCSF, San Francisco, CA, ⁹UCLA David Geffen School of Medicine, Los Angeles, CA, ¹⁰UT Southwestern Medical Center, Dallas, TX, ¹¹Cedars-Sinai Medical Center, Los Angeles, CA, ¹²Emory University, Roswell, GA, ¹³Medical College of Georgia at Augusta University, Martinez, GA, ¹⁴University of Michigan, Dexter, MI, ¹⁵University of Alabama at Birmingham (UAB), Birmingham VA Medical Center, Birmingham, AL, ¹⁶Northwell Health, Jericho, NY, ¹⁷UMass Chan Medical School, Worcester, MA, ¹⁸UCLA, Sherman Oaks, CA, ¹⁹University of Colorado Anschutz Medical Campus, Golden, CO, ²⁰University of Colorado Denver, Aurora, CO, ²¹National Institutes of Health, Rockville, MD, ²²Rho, Inc, Durham, NC, ²³Rho, Inc., Durham, NC, ²⁴Rho, Inc., Salem, IA, ²⁵NIAID/ NIH, Washington, DC, ²⁶University of Colorado, Denver, CO
Background/Purpose: Individuals with elevations of serum anti-cyclic citrullinated peptide (anti-CCP) antibodies are at-risk for rheumatoid arthritis (RA). Identification of interventions to prevent RA in anti-CCP-positive…
Abstract Number: 1370 • ACR Convergence 2025
Impact of Six-Month Monitoring Compared to Three-Month Monitoring of Labs for Methotrexate Toxicity
Spencer Simko¹, Sohini Mukherjee², Ray Zhang², Puneet Bajaj³ and Bonnie Bermas⁴, ¹University of Texas Southwestern, Dallas, TX, ²University of Texas Southwestern, Dallas, ³UT Southwestern Medical Center, Dallas, TX, ⁴UTSouthwestern.edu, Dallas, TX
Background/Purpose: Current rheumatology treatment guidelines recommend lab monitoring for methotrexate toxicity at three-month intervals for established patients. We sought to evaluate whether monitoring labs at…
Abstract Number: 1352 • ACR Convergence 2025
Prediction of 5-Year Fracture Risk in Rheumatoid and Psoriatic Arthritis Using REMS Technology
Marco Di Paola¹, Edmund J MacLaughlin², Kathleen Methric³, Maurizio Muratore⁴, Gianmarco Del Vecchio⁵, Giusy Peluso⁶, Ernesto Casciaro¹, Fabiola Rosa Contaldo⁷, Fiorella Anna Lombardi¹, Paola Pisani¹, Francesco Conversano¹ and Sergio Casciaro¹, ¹Institute of Clinical Physiology, National Research Council, Lecce, Puglia, Italy, ²Rheumatology Associates of Delmarva and BoneVue Diagnostics, Easton, MD, ³BoneVue Diagnostics, Catonsville, MD, ⁴ASL- LE, "Vito Fazzi" Hospital, Lecce, Puglia, Italy, ⁵Department of Research and Development, Echolight S.p.a., Lecce, Puglia, Italy, ⁶Department of Innovative Engineering, University of Salento, Lecce, Puglia, Italy, ⁷Department of Biological and Environmental Sciences and Technologies, University of Salento, University of Salento, Lecce, Puglia, Italy
Background/Purpose: Autoimmune arthritis, including Rheumatoid Arthritis (RA) and Psoriatic Arthritis (PA), are among the most common forms of inflammatory joint diseases. These conditions affect joints…
Abstract Number: 1335 • ACR Convergence 2025
Chest x-Ray and pulmonary function tests are not sensitive for screening intertitial lung disease in reumatoid arthritis
Jesús Loarce¹, Alonso Sebastián González Montes², SONIA JIMENEZ BARRIOS³, Mauro Ferre-Sanfrancisco⁴, Verónica García García⁵ and Javier Bachiller⁶, ¹Ramón y Cajal University Hospital, Madrid, Spain, ²Ramón y Cajal university hospital, Madrid, Madrid, Spain, ³Hospital Universitario Ramón y Cajal, Madrid, Spain, ⁴Department of Rheumatology, Hospital Universitario Ramon y Cajal, Madrid, Spain, Madrid, Madrid, Spain, ⁵Ramón y Cajal University Hospital, MADRID, Spain, ⁶Hospital Ramon y Cajal, Madrid, Madrid, Spain
Background/Purpose: Interstitial lung disease (ILD) is a frequent and severe complication of rheumatoid arthritis (RA). Although early diagnosis and screening of ILD in RA patients…
Abstract Number: 1320 • ACR Convergence 2025
Trends In Incidence and Risk factors For Incident Venous Thromboembolism in Patients with Rheumatoid Arthritis: A Population-Based Retrospective Cohort Study
Noah Frechette¹, Elena myasoedova¹, Iqra Javed¹, Roslin George¹, Sara Achenbach² and Cynthia Crowson³, ¹Mayo Clinic, Rochester, MN, ²Mayo Clinic, Rochester, ³Mayo Clinic, Stewartvillle, MN
Background/Purpose: Venous thromboembolism (VTE) is more common in patients with rheumatoid arthritis (RA) and can present as deep vein thrombosis (DVT) or pulmonary embolism (PE).…
Abstract Number: 1264 • ACR Convergence 2025
Breaking the Veil: Preliminary Findings for a Qualitative Analysis of Rheumatoid Arthritis Patient Perspectives on Physical Activity and Mental Healt
Daniel Garcia¹, Vanessa Madrigal², Noelia Hernandez³, Alisha Akinsete⁴, Iris Navarro-Millan⁵, Ileana Vazquez Otero⁶, Ariana Gonzalez Melendez⁷, Sarah Young⁸ and Monika Safford², ¹Weill Cornell, Brooklyn, NY, ²Weill Cornell Medicine, New York, ³Weill Cornell Medicine, New York, NY, ⁴Weill Cornell Medical Center, New York, NY, ⁵Weill Cornell Medicine, Hospital for Special Surgery, Poughkeepsie, NY, ⁶Clinica Reuviva, San Juan, PR, ⁷Ponce Health Sciences, San Juan, PR, ⁸Weill Cornell Medicine, Johnson City, NY
Background/Purpose: Approximately 1.3 million Americans have rheumatoid arthritis (RA)1. Up to 83% of people with chronic pain, the hallmark symptom of RA also experience anxiety…
Abstract Number: 1094 • ACR Convergence 2025
Changes in NK cells and TH cell phenotype in Rheumatoid Arthritis patients treated with janus kinase inhibitors: implications for adverse effects
Carmen Lasa Teja¹, Juan José Fernández-Cabero², Alejandra Comins-Boo³, David San Segundo³, Virginia Portilla González⁴, Montserrat Santos-Gomez⁵, José Luis Martín-Varillas⁶, Marcos López-Hoyos³ and Ricardo Blanco⁷, ¹Division of Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain., Riotuerto, Cantabria, Spain, ²Division of Immunology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander , Spain, Santander, Cantabria, Spain, ³Division of Immunology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander , Spain, Santander, Spain, ⁴Division of Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander , Spain, Santander, ⁵Division of Immunology, Hospital Sierrallana. Santander , Spain, Santander, Spain, ⁶Rheumatology Division, Hospital de Laredo. IDIVAL, Immunopathology Group. Santander, Spain., Laredo, Spain, ⁷Rheumatology Division, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain, Santander, Cantabria, Spain
Background/Purpose: Janus kinase inhibitors (JAKi) are effective in rheumatoid arthritis (RA); however, concerns regarding safety, particularly the risk of infections and malignancies, have been raised.…
Abstract Number: 1017 • ACR Convergence 2025
Effectiveness of Recombinant Zoster Vaccine in Reducing Herpes Zoster Incidence and All-Cause Mortality Among Rheumatoid Arthritis Patients: A Retrospective Cohort Study of 21,046 Individuals from TriNetX U.S. Collaborative Network
James Wei¹, Shiow-Ing Wang² and Ying-Li Lin², ¹Chung Shan Medical University Hospital, Taichung, Taichung, Taiwan (Republic of China), ²Chung Shan Medical University Hospital; China Medical University, Taichung, Taiwan (Republic of China)
Background/Purpose: Patients with rheumatoid arthritis (RA) are at increased risk of developing herpes zoster (HZ). This study aimed to assess the effectiveness of recombinant zoster…
Abstract Number: 0919 • ACR Convergence 2025
Proteomic Profiling of Extracellular Vesicles from Synovial Fluid of RA and OA Patients Reveals Cell-type-specific subpopulations and Disease Related Patterns
Stefanie Kurth¹, Andre Tiaden¹, Edveena Hanser¹, Simone Häner¹, Stavros Giaglis¹, Florian Geier¹, Dominik Burri¹, Katarzyna Buczak¹, Ute Heider², Stefan Wild², Yves Acklin¹, Christian Egloff¹ and Diego Kyburz³, ¹University of Basel, Basel, Switzerland, ²Miltenyi Biotec, Bergisch-Gladbach, Germany, ³University Hospital Basel, Basel, Switzerland
Background/Purpose: Extracellular vesicles (EVs) are secreted by virtually all cells and are known to carry bioactive cargo including proteins, RNA, DNA and metabolites. Analysis of…
Abstract Number: 0832 • ACR Convergence 2025
Elevated serum peptidylarginine deiminase 4 (PAD4) levels in anti-CCP antibody positive at-risk individuals with arthralgia who progress to rheumatoid arthritis.
Sana Sharrack¹, Xia Yu², Arun Jayaraman³, Laurence Duquenne⁴, Andrea Di Matteo⁵, Kate Harnden⁵, Lucy Thornton⁵, Helen Jayne-Sugden⁵, Jacqueline Nam⁶, Adam Smith⁵, Mia Collins⁷, Rachel Sparks³, Fanyi Jiang⁸, Kyriakos Konstantinidis⁹, Jessica Neisen¹⁰, Greet De Baets¹⁰, David Close¹¹, Chris chamberlain¹⁰, Adam Platt¹², Paul Emery¹³, Josie Meade² and Kulveer Mankia¹³, ¹Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, Sheffield, United Kingdom, ²Division of Oral Biology, School of Dentistry, University of Leeds, Leeds, United Kingdom, Leeds, United Kingdom, ³AstraZeneca, Translational Science and Experimental Medicine, Research and Early Development, Respiratory and Immunology (R&I), BioPharmaceuticals R&D, Gaithersburg, Maryland, United States of America, Gaithersburg, Maryland, ⁴Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, United Kingdom, Leeds, United Kingdom, ⁵Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, Leeds, United Kingdom, ⁶Leeds Teaching Hospitals NHS Trust, Leeds, England, United Kingdom, ⁷AstraZeneca, Gothenburg, Sweden, ⁸AstraZeneca, Translational Science and Experimental Medicine, Research and Early Development, Respiratory and Immunology (R&I), BioPharmaceuticals R&D, Gothenburg, Sweden, Gothenburg, Sweden, ⁹AstraZeneca, R&I Projects, Research and Early Development, Respiratory and Immunology (R&I), BioPharmaceuticals R&D,, Cambridge, United Kingdom, Cambridge, United Kingdom, ¹⁰AstraZeneca, Translational Science and Experimental Medicine, Research and Early Development, Respiratory and Immunology (R&I), BioPharmaceuticals R&D, Cambridge, United Kingdom, Cambridge, United Kingdom, ¹¹AstraZeneca, Royston, United Kingdom, ¹²AstraZeneca, Translational Science and Experimental Medicine, Research and Early Development, Respiratory and Immunology (R&I), BioPharmaceuticals R&D, Cambridge, United Kingdom, Melbourn, Royston,, United Kingdom, ¹³University of Leeds, Leeds, England, United Kingdom
Background/Purpose: Anti-Cyclic Citrullinated Peptide (anti-CCP) antibodies are one of the strongest risk factors for the development of rheumatoid arthritis (RA). Anti-CCP antibodies are generated against…
Abstract Number: 0532 • ACR Convergence 2025
Generative artificial intelligence provides synthetic data to discriminate patients with seronegative rheumatoid arthritis versus psoriatic arthritis sine psoriasis
Antonio Tonutti¹, Saverio D'Amico², Pierandrea Morandini², Cosimo Faeti², Elisa Barone¹, Nicoletta Luciano¹, Victor Savevski² and Carlo Selmi³, ¹Humanitas University, Pieve Emanuele, Italy, ²IRCCS Humanitas Research Hospital, Rozzano, Italy, ³Humanitas University, Milan, Italy
Background/Purpose: Distinguishing seronegative rheumatoid arthritis (RA) from psoriatic arthritis (PsA) sine psoriasis remains challenging, often relying on pathognomonic features (axial involvement, enthesitis) present in only…
Abstract Number: 0488 • ACR Convergence 2025
Early and Sustained Improvements in Disease Activity and Patient-Reported Outcomes in Patients Treated with Filgotinib for Rheumatoid Arthritis: Up to 2-Year Interim Real-World Data From FILOSOPHY and PARROTFISH
Jérôme Avouac¹, Neil Betteridge², Karen Bevers³, Gerd Burmester⁴, Roberto Caporali⁵, Ouafia Bouzid⁶, Thomas Debray⁶, Carole Van der Donckt⁶, James Galloway⁷, Susana Romero-Yuste⁸ and Patrick Verschueren⁹, ¹Hôpital Cochin, AP-HP Centre - Université Paris Cité, Paris, France, ²Neil Betteridge Associates, London, United Kingdom, ³Sint Maartenskliniek, Nijmegen, Netherlands, ⁴Department of Rheumatology and Clinical Immunology, Charité – Universitätsmedizin Berlin, Berlin, Germany, ⁵University of Milan and ASST Gaetano Pini-CTO, Milano, Italy, ⁶Alfasigma S.p.A., Bologna, Italy, ⁷King's College London, London, United Kingdom, ⁸University Hospital Complex of Pontevedra, Pontevedra, Spain, ⁹Rheumatology, University Hospital Leuven and Skeletal Biology and Engineering Research Centre, KU Leuven, Leuven, Belgium
Background/Purpose: FILOSOPHY (NCT04871919) and PARROTFISH (NCT05323591) are ongoing, prospective, observational Phase 4 studies of filgotinib in patients (pts) with rheumatoid arthritis (RA) in Europe. In…
Abstract Number: 0472 • ACR Convergence 2025
Detrimental Effects of Umbilical Cord Blood-derived Mesenchymal Stem Cells Intra-articular Injections on Pannus Invasiveness
Sung Eun Kim¹, Hye Lim Kang¹, Min Jung Kim², Hyung-Sik Kim³ and Kichul Shin⁴, ¹Division of Rheumatology, Department of Internal Medicine, SMG-SNU Boramae Medical Center, Seoul, Republic of Korea, ²Seoul Metropolitan Government Boramae Medical center, Dongjak-gu, Seoul, South Korea, ³Department of Oral Biochemistry, Pusan National University School of Dentistry, Yangsan, Republic of Korea, ⁴Seoul National University, Seoul, South Korea
Background/Purpose: Studies have shown that mesenchymal stem cell (MSC) infusion ameliorates arthritis in animal models. However, the first-pass effect in the lung has directed attention…
Abstract Number: 0456 • ACR Convergence 2025
Impact of Rheumatoid Arthritis on mortality and other outcomes in Heart failure: A nationwide analysis.
Nisha Sapkota¹, Samuel Sule-saa¹, Yubraj Aryal², Mark Ntow³, Karuna Bista⁴, Parvathy Rajeev³, jemima Alemonai³, Esther Duodu⁵, Brijesh Ghimire³, Pyae Hein³, Jeffrey Sackey⁶, Muhanned Towfig³, Robert Lamptey³, Temesgen Gobena⁷, Daniel Pinkrah⁷ and Mona Pervil Ulysse⁸, ¹Interfaith Medical Center, One Broolyn Health, Brooklyn, NY, ²Geisinger Medical Center, Danville, PA, ³Interfaith Medical Center, One Broolyn Health, Brooklyn, ⁴Montefiore New Rochelle Hospital, New Rochelle, NY, ⁵Broodale Hospital Medical Center, One Broolyn Health, Brooklyn, ⁶Interfaith Medical Center,One Broolyn Health, Brooklyn, ⁷Interfaith Medical Center, Brooklyn, NY, ⁸Interfaith Medical Center, One Brooklyn Health, Brooklyn
Background/Purpose: Rheumatoid arthritis (RA) is a chronic autoimmune disease associated with systemic inflammation and increased cardiovascular risk, particularly heart failure (HF). Patients with RA and…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].